Morgan Stanley Maintains Equal-Weight on Immunocore Holdings, Lowers Price Target to $42
Immunocore Holdings plc (IMCR) Presents at Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting - Slideshow
HC Wainwright & Co. Maintains Buy on Immunocore Holdings, Lowers Price Target to $80
Immunocore to present at upcoming investor conferences
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
Immunocore reports third quarter financial results and provides a business update
Immunocore Holdings Announces Data Form Its Phase 1/2 Study Of Brenetafusp Shows 29% Overall Response Rate, 71% Disease Control Rate
Immunocore Hldgs Q3 EPS $(0.28) Misses $(0.10) Estimate, Sales $102.222M Miss $113.438M Estimate
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Immunocore To Present Phase 1/2 Trial Data Evaluating Brenetafusp Alone And In Combination With KIMMTRAK In HLA-A*02:01-Positive Patients With Metastatic Uveal Melanoma, At 2026 SITC Annual Meeting
Should First Type 1 Diabetes Dosing Require Action From Immunocore Stock Investors?
HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
Immunocore Hldgs Q2 2026 Earnings Call Transcript
Immunocore: Advanced Cutaneous Melanoma Data Catalysts Feel Crucial
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Immunocore Holdings Announces Achievement Of Target Patient Enrollment In TEBE-AM Clinical Trial; Topline Overall Survival Data Expected As Early As End Of 2026
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
JP Morgan Reinstates Overweight on Immunocore Holdings, Announces $50 Price Target
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.